Your browser doesn't support javascript.
Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection.
Abayasingam, Arunasingam; Balachandran, Harikrishnan; Agapiou, David; Hammoud, Mohamed; Rodrigo, Chaturaka; Keoshkerian, Elizabeth; Li, Hui; Brasher, Nicholas A; Christ, Daniel; Rouet, Romain; Burnet, Deborah; Grubor-Bauk, Branka; Rawlinson, William; Turville, Stuart; Aggarwal, Anupriya; Stella, Alberto Ospina; Fichter, Christina; Brilot, Fabienne; Mina, Michael; Post, Jeffrey J; Hudson, Bernard; Gilroy, Nicky; Dwyer, Dominic; Sasson, Sarah C; Tea, Fiona; Pilli, Deepti; Kelleher, Anthony; Tedla, Nicodemus; Lloyd, Andrew R; Martinello, Marianne; Bull, Rowena A.
  • Abayasingam A; School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
  • Balachandran H; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Agapiou D; School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
  • Hammoud M; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Rodrigo C; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Keoshkerian E; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Li H; School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
  • Brasher NA; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Christ D; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Rouet R; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Burnet D; School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
  • Grubor-Bauk B; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Rawlinson W; Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.
  • Turville S; Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.
  • Aggarwal A; Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst 2010, NSW, Australia.
  • Stella AO; Virology Laboratory, Discipline of Surgery, The University of Adelaide and Basil Hetzel Institute for Translational Health Research, Adelaide 5011, SA, Australia.
  • Fichter C; School of Medical Sciences, Faculty of Medicine, UNSW Australia, Sydney, NSW, Australia.
  • Brilot F; Serology and Virology Division, Department of Microbiology, NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia.
  • Mina M; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Post JJ; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Hudson B; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Gilroy N; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Dwyer D; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
  • Sasson SC; Brain Autoimmunity Group, Kids Neurosciences Centre, Kids Research at the Children's Hospital at Westmead, Sydney, NSW, Australia.
  • Tea F; Northern Beaches Hospital, Sydney, NSW, Australia.
  • Pilli D; Prince of Wales Clinical School, UNSW Australia, Sydney, NSW Australia.
  • Kelleher A; Royal North Shore Hospital, Sydney, NSW, Australia.
  • Tedla N; Westmead Hospital, Sydney, NSW, Australia.
  • Lloyd AR; Westmead Hospital, Sydney, NSW, Australia.
  • Martinello M; The Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
  • Bull RA; Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
Cell Rep Med ; 2(4): 100228, 2021 04 20.
Article in English | MEDLINE | ID: covidwho-2247733
ABSTRACT
Considerable concerns relating to the duration of protective immunity against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) exist, with evidence of antibody titers declining rapidly after infection and reports of reinfection. Here, we monitor the antibody responses against SARS-CoV-2 receptor-binding domain (RBD) for up to 6 months after infection. While antibody titers are maintained, ∼13% of the cohort's neutralizing responses return to background. However, encouragingly, in a selected subset of 13 participants, 12 have detectable RBD-specific memory B cells and these generally are increasing out to 6 months. Furthermore, we are able to generate monoclonal antibodies with SARS-CoV-2 neutralizing capacity from these memory B cells. Overall, our study suggests that the loss of neutralizing antibodies in plasma may be countered by the maintenance of neutralizing capacity in the memory B cell repertoire.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Memory B Cells Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2021.100228

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Spike Glycoprotein, Coronavirus / SARS-CoV-2 / COVID-19 / Memory B Cells Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Cell Rep Med Year: 2021 Document Type: Article Affiliation country: J.xcrm.2021.100228